Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

771
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
771
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

1.2K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.2K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

730
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
730
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

261
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
261
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

936
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
936
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

499
Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
499

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Summary of Cardiometabolic Disorders in the Maghreb: Insights from the 2025 Saclay Cardiometabolic Summit.

Cardiology and therapy·2026
Same author

Artificial intelligence adoption in French cardiovascular care: a multiprofessional survey of barriers and facilitators.

European heart journal. Digital health·2026
Same author

Chlorhexidine vs Povidone-Iodine Alcohol Solutions for Cardiac Implantable Electronic Devices: A Prospective Randomized Study.

Journal of the American College of Cardiology·2026
Same author

Right focal atrial tachycardia following closure of patent foramen ovale with an amplatzer septal occluder device: case report.

European heart journal. Case reports·2025
Same author

[Leadless pacemakers: It's time for implantation in centers without on-site cardiac surgery].

Annales de cardiologie et d'angeiologie·2025
Same author

Defibrillation Testing During Implantation of Subcutaneous Implantable Cardioverter Defibrillators.

Journal of the American College of Cardiology·2025

Related Experiment Video

Updated: Jan 16, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.9K

[Left bundle branch area pacing and resynchronization in heart failure].

Jérôme Taieb1, Walid Amara2

  • 1Centre hospitalier Aix en Provence Avenue des Tamaris 13100 Aix en Provence, France.

Annales De Cardiologie Et D'Angeiologie
|September 30, 2025
PubMed
Summary

Left bundle branch block pacing (LBBAP) offers a reliable method for physiological ventricular activation, showing promise over traditional therapies. Ongoing research and new devices support LBBAP as a potential first-line treatment for heart rhythm disorders.

Keywords:
Aire branche gaucheHemodynamicsHemodynamiqueLeft bundle branch areaSpecialized conduction systemStimulationVoie de conduction spécialisée

More Related Videos

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.6K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

1.3K

Related Experiment Videos

Last Updated: Jan 16, 2026

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.9K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.6K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

1.3K

Area of Science:

  • Cardiology
  • Electrophysiology
  • Medical Devices

Background:

  • Left bundle branch block pacing (LBBAP) is an emerging technique for achieving physiological ventricular activation.
  • It presents a more reliable alternative to Hisian pacing and can address proximal left bundle branch block.
  • Growing evidence from registries and early trials suggests LBBAP's efficacy.

Purpose of the Study:

  • To evaluate the benefits of LBBAP compared to conventional cardiac resynchronization therapy.
  • To assess the technical reliability and clinical outcomes of LBBAP.
  • To inform the development of dedicated LBBAP equipment.

Main Methods:

  • Analysis of data from numerous registries and initial small-scale randomized studies.
  • Comparison of LBBAP outcomes against conventional resynchronization therapy.
  • Ongoing development and integration of LBBAP into defibrillation leads by manufacturers.

Main Results:

  • Encouraging results favor LBBAP over conventional resynchronization therapy in initial studies.
  • LBBAP demonstrates technical reliability and potential for correcting conduction abnormalities.
  • Consensus documents recognize LBBAP as a viable first-line option and recommend it post-conventional therapy failure.

Conclusions:

  • Left bundle branch block pacing is a promising strategy for physiological ventricular activation.
  • LBBAP shows superiority or equivalence to conventional therapies in early evaluations.
  • Further robust randomized studies are in progress to solidify LBBAP's role in cardiac rhythm management.